RoosterBio Inc. raised almost $5.2 million in equity and option, according to a filing Monday with the Securities and Exchange Commission.
RoosterBio filed a Form D signed by CEO Margot Connor, founder and Chief Technical Officer Jon Rowley and Robert Carlson on Feb. 27.
RoosterBio, founded in 2012, is a biotechnology company that works on cell-based bioeconomy and provides standardized stem cell technology to bring products to market faster.
The $5,197,557 has been raised from 10 investors.
This is an amended notice with the first date of sale on Nov. 23, 2016. This offering is not intended to last more than one year.
The types of securities offered are in equity and option, warrant or other right to acquire another security.
The company has over 160 customers worldwide and started offering products to customers in February 2014. The company website equates biofabrication of stem cells to 3D printing. The company products include cells, media and kits and bundles.
None of the money will go toward executive salary, and the offering is not being made in conjunction with a business combination transaction. There is no minimum investment accepted from any outside investor.
The company claimed a Rule 506 (b) exemption for the filing. Companies relying on the Rule 506 exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.
